Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK, Valeant Willing To Exclude Some Epilepsy Patients From Potiga Market

Executive Summary

GlaxoSmithKline and Valeant Pharmaceuticals appear willing to sacrifice a part of the target market for their anti-epileptic drug Potiga (ezogabine), as well as implement an extensive Risk Evaluation and Mitigation Strategy, in order to gain approval

You may also be interested in...



Five Positive Opinions From EU's CHMP Brightens Up The New Year

New molecular entities from Valeant/GSK, Eisai, Sanofi and Novartis make the grade for the EU's scientific panel at its January meeting.

Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug

Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.

Narrower Indication, New Studies Are Likely Riffs For Jazz Fibromyalgia Drug

Jazz Pharmaceuticals will likely have to narrow the proposed indication for its fibromyalgia drug JZP-6 (sodium oxybate) following a "complete response" letter from FDA, but that appears to be only the first step for the product.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel